Autoimmune Disorder

Autoimmune Disorder-related patent applications - as published by the U.S. Patent and Trademark Office (USPTO).

Image View List View Download All PDFs Archive

loading
NEW Immune regulatory oligonucleotide (iro) compounds to modulate toll-like receptor based immune response
May 25, 2017 - N°20170145417

The invention provides novel immune regulatory oligonucleotides (iro) as antagonist of tlrs and methods of use thereof. These iros have unique sequences that inhibit or suppress tlr-mediated signaling in response to a tlr ligand or tlr agonist. The methods may have use in the prevention and treatment of cancer, an autoimmune disorder, airway inflammation, inflammatory disorders, infectious disease, skin disorders, ...
NEW Crystalline forms and processes for the preparation of cannabinoid receptor modulators
May 25, 2017 - N°20170144993

The present invention relates to crystalline forms of (1as,5as)-2-(4-oxy-pyrazin-2-yl)-1a,2,5,5a-tetrahydro-1h-2,3-diaza-cyclopropa[a]pentalene-4-carboxylic acid ((s)-1-hydroxymethyl-2,2-dimethyl-propyl)-amide (compound 1) and pharmaceutical compositions thereof that modulate the activity of the cannabinoid cb2 receptor and are therefore useful in the treatment of cb2 receptor-mediated disorders, for example, osteoarthritis; pain; hyperalgesia; allodynia; inflammatory ...
NEW Use of cinnabarinic acid as a modulator of immune response in autoimmune disorders
May 25, 2017 - N°20170143727

The present invention provides compounds and methods for preventing and treating an immune disorder in a subject.
NEW Autoimmune Disorder Patent Pack
Download + patent application PDFs
Autoimmune Disorder Patent Applications
Download + Autoimmune Disorder-related PDFs
For professional research & prior art discovery
inventor
  • + full patent PDF documents of Autoimmune Disorder-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
NEW Selective kinase inhibitors
May 25, 2017 - N°20170143706

The present disclosure relates to methods of modulating (for example, inhibiting) activity of jak3, comprising contacting the jak3 with a compound of formula i or pharmaceutically acceptable salt thereof, wherein constituent members are provided hereinwith. The present disclosure further provides novel compounds and compositions as well as their methods of preparation and use. The disclosed jak3 inhibitors may be used ...
Tiopronin prodrugs, pharmaceutical compositions thereof, and methods of use
May 11, 2017 - N°20170129867

Tiopronin prodrugs, pharmaceutical compositions comprising the tiopronin prodrugs, and methods of using tiopronin prodrugs and pharmaceutical compositions thereof for treating liver, kidney, lung, neurological, inflammatory, and autoimmune disorders including non-alcoholic steatohepatitis, wilson's disease, cystinuria, irritable bowel disorder, ulcerative colitis, rheumatoid arthritis, chronic obstructive pulmonary disease, interstitial lung disease, asthma, cystic fibrosis, parkinson's disease, and huntington's disease.
New pharmaceutical compositions and their use for the treatment of autoimmune disorders
Universite Grenoble Alpes
May 11, 2017 - N°20170128536

A pharmaceutical composition in which the active substance includes or is: (i) a protein including the sequence seq id no: 1, representing the april protein, (ii) any derived protein, which is derived from protein of sequence seq id no: 1 by substitution, removal or addition of one or more amino-acids, provided it allows the binding of the derived protein to an astrocyte ...
Autoimmune Disorder Patent Pack
Download + patent application PDFs
Autoimmune Disorder Patent Applications
Download + Autoimmune Disorder-related PDFs
For professional research & prior art discovery
inventor
  • + full patent PDF documents of Autoimmune Disorder-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Dipeptides as inhibitors of human immunoproteasomes
Cornell University
May 04, 2017 - N°20170121366

The compounds of the present invention are represented by the following compounds having formula (i) where the substituents r1-r10, x, y, k, m, n, q, and s are as defined herein. These compounds are used in the treatment of cancer, immunologic disorders, autoimmune disorders, neurodegenerative disorders, or inflammatory disorders or for providing immunosuppression for transplanted organs or tissues.
Expression of mirnas in placental tissue
Cornell University
April 27, 2017 - N°20170114343

Provided are human mirnas associated with the generation of immunological tolerance during pregnancy as well as fragments, derivatives and variants thereof for use in immunomodulation. Said mirnas may be used in diagnosis and treatment of disorders associated with a deregulated immune response, autoimmune disorders, pregnancy associated diseases, failure or problems of placentation and complications resulting from allotransplantations. In addition, new ...
Benzimidazole derivatives as pi3 kinase inhibitors
Glaxosmithkline Llc
April 27, 2017 - N°20170112844

This invention relates to the use of benzimidazole derivatives for the modulation, notably the inhibition of the activity or function of the phosphoinositide 3′ oh kinase family (hereinafter pi3 kinases), suitably, pi3kα, pi3kδ, pi3kβ, and/or pi3kγ. Suitably, the present invention relates to the use of benzimidazoles in ...
Methods and compositions for treating autoimmune and inflammatory conditions
Baylor Research Institute
April 20, 2017 - N°20170106051

Described herein are compositions and methods for inhibiting an inflammatory or autoimmune response and for inducing immune tolerance in a subject in need thereof comprising administering to the subject a therapeutically effective amount of an antigen presenting cell (apc)-targeted antibody operatively linked to il-10 or a fragment thereof. The compositions and methods described herein are useful for treating inflammatory ...
Systems and methods of improving an immune disorder
Ohio State Innovation Foundation
April 13, 2017 - N°20170100605

Methods for improving an immune disorder in a subject are provided. The immune disorder can be an autoimmune disorder, a hypersensitivity syndrome, or an immune deficiency syndrome. Methods include positioning a therapy delivery device on a neural target site that contributes to immune activity of the subject. The therapy delivery device is activated to deliver a therapy signal to the ...
Dna aptamers specific to cd200r1 and their therapeutic uses
D5pharma Inc.
April 06, 2017 - N°20170096670

Disclosed are short dna aptamers that selectively recognize cd200r1, a protein expressed on the surface of myeloid and lymphoid cells that delivers immune inhibitory signals to modulate inflammation when engaged with its ligand, cd200. Also disclosed is the use of said aptamers as therapeutic agents, for the purpose of decreasing inflammatory response; treatment of spinal cord injury; treatment of ...
Cysteine, n-acetylcysteine, and penicillamine related compounds, pharmaceutical compositions thereof, and methods of use
D5pharma Inc.
March 23, 2017 - N°20170081280

Cysteine, n-acetylcysteine, and penicillamine related compounds, pharmaceutical compositions comprising the cysteine, n-acetylcysteine, and penicillamine related compounds, and methods of using cysteine, n-acetylcysteine, and penicillamine related compounds and pharmaceutical compositions thereof for treating liver, kidney, lung, neurological, inflammatory, and autoimmune disorders including paracetamol overdose, non-alcoholic steatohepatitis, wilson's disease, cystinuria, irritable bowel disorder, ulcerative colitis, rheumatoid arthritis, chronic obstructive pulmonary disease, interstitial ...
Autoimmune Disorder Patent Pack
Download + patent application PDFs
Autoimmune Disorder Patent Applications
Download + Autoimmune Disorder-related PDFs
For professional research & prior art discovery
inventor
  • + full patent PDF documents of Autoimmune Disorder-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Bacteria engineered to treat diseases that benefit from reduced gut inflammation and/or tightened gut ...
Synlogic, Inc.
March 09, 2017 - N°20170067065

Genetically engineered bacteria, pharmaceutical compositions thereof, and methods of treating or preventing autoimmune disorders, inhibiting inflammatory mechanisms in the gut, and/or tightening gut mucosal barrier function are disclosed.
Amido compounds as roryt modulators and uses thereof
Synlogic, Inc.
March 09, 2017 - N°20170065606

And wherein n1, n2, r1a, r1b, r2, r3, r4, r5, and r6 are as described herein. The compounds may be prepared as pharmaceutical compositions, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, inflammatory conditions, autoimmune disorders, cancer, and graft-versus-host disease.
Induced expression of brain derived neurotrophic factor (bdnf) for treatment of neuromuscular, neurodegenerative, autoimmune, developmental ...
Mitochon Pharmaceuticals, Inc.
March 09, 2017 - N°20170065536

A method of treating a host of neuromuscular, neurodegenerative, developmental, autoimmune and metabolic diseases/disorders related to aging, such as traumatic injury, stroke, huntington's disease, epilepsy, multiple sclerosis (ms), lupus, type-1 and type-2 diabetes, maturity onset diabetes of the young (mody), myasthenia gravis (mg), rheumatoid arthritis (ra), graves' disease, guillain-barré syndrome (gbs), metabolic syndrome, muscular dystrophy or duchenne muscular ...
Human antibodies that bind cd22 and uses thereof
E. R. Squibb & Sons, L.l.c.
March 02, 2017 - N°20170058031

The present disclosure provides isolated monoclonal antibodies that specifically bind to cd22 with high affinity, particularly human monoclonal antibodies. Nucleic acid molecules encoding the antibodies of this disclosure, expression vectors, host cells and methods for expressing the antibodies of this disclosure are also provided. Antibody-partner molecule conjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of this disclosure are also ...
Fumarate compounds, pharmaceutical compositions thereof, and methods of use
E. R. Squibb & Sons, L.l.c.
March 02, 2017 - N°20170056358

Fumarate compounds, pharmaceutical compositions comprising the fumarate compounds, and methods of using fumarate compounds and pharmaceutical compositions for treating neurodegenerative, inflammatory, and autoimmune disorders including multiple sclerosis, psoriasis, irritable bowel disorder, ulcerative colitis, arthritis, chronic obstructive pulmonary disease, asthma, parkinson's disease, huntington's disease, and amyotrophic lateral sclerosis are disclosed.
Autoimmune disorder treatment using rxr agonists
Dartmouth College
March 02, 2017 - N°20170056348

The present specification provides rxr agonist compounds, compositions comprising such rxr agonists, and methods using such compounds and compositions to treat an autoimmune disorder, inflammation associated with an autoimmune disorder and/or a transplant rejection as well as use of such rxr agonists to manufacture a medicament and use of such compounds and compositions to treat an autoimmune disorder, inflammation ...
Compositions and methods for use in combination for the treatment and diagnosis of autoimmune diseases
The Children's Hospital Of Philadelphia
February 23, 2017 - N°20170051351

This disclosure provides new genetic targets, diagnostic methods, and therapeutic treatment regimens for multiple autoimmune disorders, including pediatric autoimmune disorders that are co-inherited and genetically shared. The disclosure, for example, provides methods of diagnosing or determining a susceptibility for one or more autoimmune diseases and methods of determining treatment protocols for patients with one or more autoimmune diseases based on ...
Method of providing monoclonal auto-antibodies with desired specificity
Immunoqure Ag
February 23, 2017 - N°20170051053

Provided are novel binding molecules of human origin, particularly human antibodies as well as fragments, derivatives and variants thereof that recognize antigens such as native endogenous proteins associated with, e. G., immune response, autoimmune disorders, inflammatory diseases, metabolic disorders, vascular function, neurodegenerative diseases or tumors. More particularly, a human auto-immunosome and corresponding monoclonal antibody reservoir are provided. In addition, pharmaceutical ...